Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2015, Article ID 582163, 5 pages
http://dx.doi.org/10.1155/2015/582163
Clinical Study

The Effect of Intravenous Iron Treatment on Quality of Life in Inflammatory Bowel Disease Patients with Nonanemic Iron Deficiency

Department of Gastroenterology, İzmir Atatürk Training and Research Hospital, Izmir Kâtip Çelebi University, Karabaglar, 35160 İzmir, Turkey

Received 16 September 2014; Revised 22 December 2014; Accepted 5 January 2015

Academic Editor: Giorgos Bamias

Copyright © 2015 Cem Çekiç et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Iron deficiency is the prevalent complication of inflammatory bowel disease (IBD). Herein, we investigated the effect of intravenous iron treatment on quality of life (QoL) in nonanemic and iron deficient IBD patients. Methods. Eighty-five IBD patients were recruited for this study. The patients were intravenously administered 500 mg iron sucrose in the first week of the study. Hematologic parameters and QoL were evaluated before to iron treatment and during the 12th week of treatment. The Inflammatory Bowel Disease Questionnaire (IBDQ) and the Short Form-36 (SF-36) Health Survey were used to assess QoL. Results. Prior to intravenous iron administration, the IBDQ, SF-36 Physical Component Summary (PCS) and Mental Component Summary (MCS) scores were , , and , respectively. In the 12th week of iron administration, those scores were (), (), and (), respectively, which were all significantly different from the scores prior to iron administration. The mean changes in the IBDQ scores for ulcerative colitis and Crohn’s disease were 8.7% and 3.0% (), were 6.4% and 4.7% () for the SF-36 PCS, and were 4.6% and 3.2% () for the SF-36 MCS, respectively. Conclusion. Intravenous iron treatment may improve QoL in nonanemic, but iron deficient, IBD patients.